Previous 10 | Next 10 |
Gainers: Xenon Pharmaceuticals XENE +76%, Milestone Scientific (NYSE:MLSS) +15%, Clene (NASDAQ:CLNN) +12%, OpGen OPGN +11%, Adverum Biotechnologies ADVM +8%. Losers: Owlet (NYSE:OWLT) -25, REGENXBIO (NASDAQ:RGNX) -21%, Omeros (NASDAQ...
Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek - Patient fecal samples were evaluated for C. difficile culture and microbiome changes - Ph2a trial demonstrated 100% clinical cure and sustained clinical cure - Favorable microbiome c...
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 PR Newswire WASHINGTON , Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and s...
Acurx Pharmaceuticals to Participate in the A.G.P. Biotech and Specialty Pharma Conference October 13, 2021 PR Newswire STATEN ISLAND, N.Y. , Sept. 29, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical sta...
Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 Conference PR Newswire STATEN ISLAND, N.Y. , Sept. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: A...
Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company New York, New York--(Newsfile Corp. - September 13, 2021) - Acurx Pharmaceuticals (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company developing a new class of antibiotics t...
Acurx Pharmaceuticals to Join the Russell Microcap Index® PR Newswire STATEN ISLAND, N.Y. , Sept. 2, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class...
Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 PR Newswire STATEN ISLAND, N.Y. , Aug. 31, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a cl...
Antibiotic resistant bacteria are increasing. Overuse/misuse of antibiotics have had dire consequences. No new classes of antibiotics have been developed in almost 40 years. Significant new government incentives are proposed. Acurx Pharmaceuticals is developing new drugs f...
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update Successful June 2021 IPO Raising $17.25 million in Gross Proceeds Including Exercise of Overallotment Option PR Newswire STATEN ISLAND, N.Y. , Aug. 16, 2021 /PRNewswi...
News, Short Squeeze, Breakout and More Instantly...
Acurx Pharmaceuticals Inc. Company Name:
ACXP Stock Symbol:
NASDAQ Market:
Acurx Pharmaceuticals Inc. Website:
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome PR Newswire STATEN ISLAND, N.Y. , July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:...
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "...
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference PR Newswire Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including inc...